Updated results from the Phase III ADAURA Trial: disease-free survival with adjuvant osimertinib versus placebo for the treatment of resected EGFR-mutated stage IB-IIIA non–small-cell lung cancer
In this medfyle
An updated analysis of the phase III ADAURA trial from the article Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial by Herbst RS et al. demonstrated that adjuvant osimertinib improved DFS in resected EGFR-mutated NSCLC, and in the patient subgroups analyzed.
About this Medfyle
©Copyright Medfyle 2023
Original article:
Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, Kato T, Goldman JW, Laktionov K, Kim SW, Yu CJ, Vu HV, Lu S, Lee KY, Mukhametshina G, Akewanlop C, de Marinis F, Bonanno L, Domine M, Shepherd FA, Urban D, Huang X, Bolanos A, Stachowiak M, Tsuboi M. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023 Apr 1;41(10):1830-1840. doi: 10.1200/JCO.22.02186. Epub 2023 Jan 31. Erratum in: J Clin Oncol. 2023 Apr 27;:JCO2300658. PMID: 36720083; PMCID: PMC10082285.
The summary content was prepared by by Louise Gardner for Medfyle, and reviewed by Marianna Aita, MD.
The authors of the original article and the publisher were not involved in the creation of the summary.
